Reducing prostaglandin E2 production to raise cancer immunogenicity.
AffiliationCancer Inflammation and Immunity Group, Cancer Research UK Manchester Institute, The University of Manchester , Manchester
MetadataShow full item record
AbstractCyclooxygenases (COX), commonly upregulated in numerous cancers, generate prostaglandin E2 (PGE2), which has been implicated in key aspects of malignant growth including proliferation, invasion and angiogenesis. Recently, we showed that production of PGE2 by cancer cells dominantly enables progressive tumor growth via immune escape and that cyclooxygenase inhibitors synergize with immunotherapy to enhance tumor eradication.
CitationReducing prostaglandin E2 production to raise cancer immunogenicity. 2016, 5 (5):e1123370 Oncoimmunology
- Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity.
- Authors: Zelenay S, van der Veen AG, Böttcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, Quezada SA, Sahai E, Reis e Sousa C
- Issue date: 2015 Sep 10
- Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity.
- Authors: Liu B, Qu L, Yan S
- Issue date: 2015
- Cyclooxygenases and prostaglandin E2 receptors in growth plate chondrocytes in vitro and in situ--prostaglandin E2 dependent proliferation of growth plate chondrocytes.
- Authors: Brochhausen C, Neuland P, Kirkpatrick CJ, Nüsing RM, Klaus G
- Issue date: 2006
- Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4.
- Authors: Ochs K, Ott M, Rauschenbach KJ, Deumelandt K, Sahm F, Opitz CA, von Deimling A, Wick W, Platten M
- Issue date: 2016 Mar
- Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer.
- Authors: Bronger H, Kraeft S, Schwarz-Boeger U, Cerny C, Stöckel A, Avril S, Kiechle M, Schmitt M
- Issue date: 2012 Feb 14